CTI BioPharma is a Seattle-based commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has FDA-approved VONJO® (pacritinib), a JAK2, ACVR1, and IRAK1 inhibitor for the treatment of myelofibrosis. See full prescribing information at www.VONJO.com.
CTI is committed to helping patients and providers access VONJO using our secure portal, www.CTIaccess.com, or by calling 888-CTI-FORU